Loading
Most cancer drugs are tested in mice with no immune system, then given to people who have one. Mice carrying the same patient's immune cells and tumour would be a fairer test.
Standard PDX models use immunodeficient mice, which cannot evaluate immunotherapy or immune-mediated toxicity. Humanised immune system mice reconstituted with HLA-matched or autologous haematopoietic cells, ideally with human cytokine knock-in backgrounds to support myeloid development, allow tumour and immune system from the same donor. Cost and reproducibility have kept them niche.
Shares Champions Oncology, Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients, Immune checkpoint inhibitors.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.